EMBARGOED UNTIL 00.01 TUESDAY 30 APRIL
MAIDENHEAD, UK, 30 April, 2019 –AbbVie welcomes the award of a contract by NHS England to continue working in partnership to facilitate the identification and treatment of hepatitis C (HCV) patients in England. This is an important step towards bringing closer the goal of NHS England (NHSE) to eliminate hepatitis C in England by 2025.
“Our aim to bring well-tolerated, highly effective and curative treatments to patients that need them, and to eliminate this chronic disease as a burden to the healthcare system, is today closer to being achieved,” said Joette Gdovin PhD, Head of UK Market Access, AbbVie UK. “We have worked closely with NHS England to build an HCV elimination strategy and we appreciate that the NHSE tender model will ensure availability of all suitable treatments in England.”
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.